This is an multicenter, randomized, controlled, parallel group study. ST-Segment Elevation Myocardial Infarction (STEMI) patients with high thrombus burden(HTB) will be allocated to one of the following: intrathrombus thrombolysis or manual aspiration thrombectomy during primary percutaneous coronary intervention(PPCI).
The hypothesis for ATTRACTIVE trial is that the intrathrombus thrombolysis with microcatheter or pierced balloon compared to manual aspiration thrombectomy will reduce the incidence of major adverse cardiovascular events(MACEs), including cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or heart failure rehospitalization, stent thrombosis and target-vessel revascularization at 1 year in STEMI patients with HTB undergoing PPCI.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
2,500
Intrathrombus Thrombolysis During Primary PCI
Aspiration Thrombectomy During Primary PCI
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
RECRUITINGRate of major adverse cardiovascular events (MACEs)
Rate of composite of cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or heart failure readmission, stent thrombosis and target-vessel revascularization
Time frame: up to 180 days
Rate of ischemic stroke and transient ischemic attack (TIA)
Rate of ischemic stroke and transient ischemic attack (TIA) at 30 days
Time frame: up to 30 days
Rate of major bleeding evens (BARC type 2, 3 and 5)
Rate of major bleeding evens (BARC type 2, 3 and 5) at 30 days
Time frame: up to 30 days
Rate of key net benefit outcome
cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or heart failure readmission, stent thrombosis, target-vessel revascularization, stroke and major bleeding evens (BARC 2,3 and 5)
Time frame: up to 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.